Key Financials Snapshot

TTM · Standalone · ₹ in Cr
Market Cap
₹18 Cr.
Stock P/E
9.1
P/B
0.3
Current Price
₹12.9
Book Value
₹ 49.1
Face Value
10
52W High
₹24.9
52W Low
₹ 11.5
Dividend Yield
0%

Nidan Labs. & Health Overview

Business

Nidan Laboratories And Healthcare Ltd. is an India-based company primarily engaged in providing diagnostic services, including pathology and imaging services. The company operates a network of diagnostic centers (Nidan Labs) and also runs Nidan Clinics that offer consultations and basic healthcare services. Their core business model revolves around offering a comprehensive range of diagnostic tests to individuals and referring doctors, generating revenue from the fees charged for these services. They focus on expanding their network of labs and collection centers, predominantly in North India.

Revenue Mix

The company's revenue is primarily derived from its diagnostic services, encompassing both pathology (blood tests, urine tests, etc.) and imaging (X-rays, ultrasound, etc.) services. While precise segment-wise revenue breakdown is not readily available in public domains, it can be inferred that diagnostic services form the overwhelming majority of their income. Revenue from Nidan Clinics providing consultations would be a smaller, supplementary component.

Industry

Nidan Laboratories operates in the highly competitive and fragmented Indian Hospital & Healthcare Services sector, specifically within the diagnostics and outpatient services market. This market is characterized by the presence of large national chains (e.g., Dr. Lal PathLabs, Metropolis Healthcare, Thyrocare Technologies), regional players, and a vast number of standalone, unorganized laboratories. Nidan is positioned as a regional player, primarily serving Delhi NCR, Haryana, and Uttar Pradesh, competing on service quality, turnaround time, and localized pricing, often targeting semi-urban and tier-2/3 areas for expansion.

MOAT

As a relatively smaller and regional player, Nidan Laboratories currently possesses a limited competitive moat. Potential advantages, though nascent, may include:

Localized Network & Brand Recognition: Developing a regional brand presence and an established network of collection centers in its operating areas can offer some stickiness.

Operational Efficiency: For smaller setups, efficient operations and quick turnaround times can be a differentiator.

However, these are generally not strong, durable moats against larger, well-funded national chains with extensive infrastructure, deeper pockets for technology, and stronger brand equity.

Growth Drivers

Increasing Health Awareness & Penetration: Growing health consciousness, rising disposable incomes, and the shift from curative to preventive healthcare in India are driving demand for diagnostic services.

Expansion of Network: The company's strategy to expand its network of labs, collection centers, and clinics, particularly in underserved semi-urban and rural areas, can drive volume growth.

Technological Advancements: Adoption of new diagnostic technologies and tests can expand service offerings and attract more customers.

Aging Population & Lifestyle Diseases: The growing elderly population and increasing incidence of chronic and lifestyle diseases necessitate regular diagnostic monitoring.

Risks

Intense Competition: The presence of numerous organized and unorganized players leads to pricing pressure and makes market share gains challenging.

Regulatory Changes: The healthcare sector is subject to evolving regulations regarding pricing, quality standards, and data privacy, which can impact operations and profitability.

Talent Acquisition & Retention: Difficulty in attracting and retaining skilled pathologists, radiologists, and technicians can affect service quality and expansion plans.

Geographic Concentration: High reliance on specific regions (North India) exposes the company to regional economic downturns or competitive intensity.

Capital Intensity: Expansion of diagnostic networks and investment in advanced equipment require significant capital expenditure.

Management & Ownership

Nidan Laboratories And Healthcare Ltd. is promoted by Dr. Ram Pratap Singh and Dr. Sunita Singh, who also serve on the board. Dr. Ram Pratap Singh, with his experience in pathology, leads the company. Being an SME-listed company, promoter ownership is typically high, demonstrating commitment. The overall quality and depth of management beyond the promoters would be crucial for scalable growth and execution in a competitive environment.

Outlook

Nidan Laboratories operates in a structurally growing Indian diagnostics market, driven by favorable demographic trends and increasing healthcare spending. The company's strategy to expand its regional footprint positions it to capitalize on this growth. However, its small size and limited brand equity compared to established national players mean it faces significant execution challenges, intense competition, and potential pricing pressures. Sustained growth will depend on its ability to effectively scale its operations, maintain service quality, attract talent, and manage capital efficiently, all while navigating a highly competitive landscape.

Nidan Labs. & Health Share Price

Live · NSE · Inception: 2000
₹ | |
Volume
Price

Key Financials — Profit & Loss

₹ in Cr · Standalone · annual

Nidan Labs. & Health Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Nidan Labs. & Health Profit & Loss

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
Net Sales 20 21 20 30 24 24 25
Other Income 0 0 1 0 3 3 2
Total Income 20 21 21 30 28 27 27
Total Expenditure 12 14 11 20 17 18 19
Operating Profit 8 8 10 10 10 9 7
Interest 5 4 3 3 2 2 2
Depreciation 3 3 3 3 3 3 2
Exceptional Income / Expenses 0 0 0 0 0 -7 0
Profit Before Tax 0 1 3 5 5 -2 3
Provision for Tax 0 0 1 2 1 1 1
Profit After Tax 0 1 2 3 4 -3 2
Adjustments 0 0 0 0 0 0 0
Profit After Adjustments 0 1 2 3 4 -3 2
Adjusted Earnings Per Share 0 0 2.3 1.9 2.5 -2.3 1.4

Nidan Labs. & Health Balance Sheet

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Shareholder's Funds 10 11 13 66 69 66 68
Minority's Interest 0 0 0 0 0 0 0
Borrowings 32 34 14 9 5 4 4
Other Non-Current Liabilities -0 -0 -0 -0 0 -0 -0
Total Current Liabilities 1 -0 26 13 10 11 10
Total Liabilities 43 45 53 88 84 82 82
Fixed Assets 23 20 20 20 21 18 16
Other Non-Current Assets 1 1 11 42 42 34 55
Total Current Assets 19 24 23 25 21 30 11
Total Assets 43 45 53 88 84 82 82

Nidan Labs. & Health Cash Flow

#(Fig in Cr.) Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Opening Cash & Cash Equivalents 0 4 7 7 8 8 3
Cash Flow from Operating Activities 9 5 4 8 11 6 2
Cash Flow from Investing Activities 1 -0 -3 -36 -0 -11 -0
Cash Flow from Financing Activities -6 -2 -1 29 -10 -0 -3
Net Cash Inflow / Outflow 4 3 -0 1 0 -6 -1
Closing Cash & Cash Equivalent 4 7 7 8 8 3 2

Nidan Labs. & Health Ratios

# Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Earnings Per Share (Rs) 0 0 2.33 1.92 2.55 -2.33 1.42
CEPS(Rs) 3.49 3.94 5.54 3.81 4.78 -0.26 3.16
DPS(Rs) 0 0 0 0 0 0 0
Book NAV/Share(Rs) 0 0 13.47 47.41 49.96 47.63 49.05
Core EBITDA Margin(%) 39.1 35.67 43.61 31.74 28.04 26.65 20.64
EBIT Margin(%) 24.8 20.82 33.19 24.23 28.99 -0.78 19.99
Pre Tax Margin(%) 1.11 3.34 16.21 15.24 19.83 -9.8 11.25
PAT Margin (%) 1.11 3.34 11.3 8.98 14.59 -13.37 8.06
Cash Profit Margin (%) 17.24 18.23 26.93 17.85 27.35 -1.52 17.88
ROA(%) 0.52 1.63 4.68 3.76 4.12 -3.9 2.41
ROE(%) 2.17 6.7 18.9 6.72 5.23 -4.77 2.94
ROCE(%) 11.71 10.15 13.98 10.52 8.5 -0.24 6.21
Receivable days 102.1 94.15 97.3 66.41 85.65 49.45 13.34
Inventory Days 1.38 1.38 1.72 1.98 4.37 5.04 6.32
Payable days 116.21 26.19 91.4 144.01 227.04 168.52 397.84
PER(x) 0 0 0 17.33 13.29 0 11.64
Price/Book(x) 0 0 0 0.7 0.68 0.57 0.34
Dividend Yield(%) 0 0 0 0 0 0 0
EV/Net Sales(x) 1.88 1.72 1.99 1.93 2.04 1.95 1.31
EV/Core EBITDA(x) 4.59 4.82 4.09 5.84 4.89 5.13 4.41
Net Sales Growth(%) 0 6.71 -4.81 45.55 -18.19 -0.36 1.45
EBIT Growth(%) 0 -10.42 51.76 6.23 -2.09 -102.67 2707.12
PAT Growth(%) 0 219.73 222.21 15.65 32.92 -191.32 161.16
EPS Growth(%) 0 0 222.21 -17.63 32.92 -191.32 161.16
Debt/Equity(x) 3.12 3.11 2.85 0.29 0.16 0.19 0.16
Current Ratio(x) 33.07 -142.02 0.88 1.98 2.18 2.67 1.1
Quick Ratio(x) 32.94 -141.52 0.87 1.96 2.14 2.65 1.05
Interest Cover(x) 1.05 1.19 1.95 2.7 3.16 -0.09 2.29
Total Debt/Mcap(x) 0 0 0 0.42 0.23 0.33 0.48

Growth Rates

Compounded annual
# 1 Year 3 Year 5 Year 10 Year
Sales CAGR +4% -6% +4% —
Operating Profit CAGR -22% -11% -3% —
PAT CAGR — -13% +15% —
Share Price CAGR -30% -25% — —
ROE Average +3% +1% +6% +5%
ROCE Average +6% +5% +8% +9%

Nidan Labs. & Health Shareholding Pattern

Latest · Jun 2026
100% held
Promoters 57.04 %
FII 0 %
DII (MF + Insurance) 0 %
Public (retail) 42.96 %
# Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026
Promoter 71.2271.2262.7957.0457.0457.0457.0457.0457.0457.04
FII 0000000000
DII 0000000000
Public 28.7828.7837.2142.9642.9642.9642.9642.9642.9642.96
Others 0000000000
Total 100100100100100100100100100100

Nidan Labs. & Health Peer Comparison

Hospital & Healthcare Services Edit Columns

Nidan Labs. & Health Quarterly Price

10-year quarterly close · BSE
Show Value Show %

News & Updates

See more…

Nidan Labs. & Health Pros & Cons

Pros

  • Stock is trading at 0.3 times its book value
  • Company is almost debt free.

Cons

  • Company has a low return on equity of 1% over the last 3 years.
  • Debtor days have increased from 168.52 to 397.84days.
Want to Start Investing in Top Unlisted Stocks?

Our experts help you choose the right stocks based on performance, risk, and growth potential.

whatsapp